311 related articles for article (PubMed ID: 32211792)
21. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
23. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
25. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
26. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Morita M; Tamiya M; Fujimoto D; Tamiya A; Suzuki H; Hirano K; Fukuda Y; Yokoyama T; Kominami R; Kanazu M; Uchida J; Hara S; Yamashita S; Tomioka H
BMC Cancer; 2020 Feb; 20(1):93. PubMed ID: 32013910
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
28. [Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].
Zhi X; Li W; Wang S; Wang J
Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):779-785. PubMed ID: 31874674
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series.
Inaba-Higashiyama R; Yoshida T; Jo H; Shirasawa M; Motoi N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3618-3621. PubMed ID: 33085191
[TBL] [Abstract][Full Text] [Related]
30. Concurrent High PD-L1 Expression and CD8
Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Miyakoshi J; Yoshida T; Kashima J; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Shiraishi K; Kohno T; Yamamoto N; Yatabe Y; Suzuki T; Ohe Y
Lung Cancer; 2024 May; 191():107788. PubMed ID: 38593478
[TBL] [Abstract][Full Text] [Related]
32. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
33. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Pai-Scherf L; Blumenthal GM; Li H; Subramaniam S; Mishra-Kalyani PS; He K; Zhao H; Yu J; Paciga M; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Nov; 22(11):1392-1399. PubMed ID: 28835513
[TBL] [Abstract][Full Text] [Related]
34. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Baba K; Tanaka H; Sakamoto H; Shiratori T; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Tasaka S
Thorac Cancer; 2019 Feb; 10(2):369-372. PubMed ID: 30600919
[TBL] [Abstract][Full Text] [Related]
36. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
[TBL] [Abstract][Full Text] [Related]
37. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
38. Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations.
Taniguchi Y; Tamiya A; Ishii S; Atagi S
Ann Oncol; 2018 May; 29(5):1331-1333. PubMed ID: 29522162
[No Abstract] [Full Text] [Related]
39. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with
Cho JH; Zhou W; Choi YL; Sun JM; Choi H; Kim TE; Dolled-Filhart M; Emancipator K; Rutkowski MA; Kim J
Cancer Res Treat; 2018 Jan; 50(1):95-102. PubMed ID: 28301925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
